Skip to main content
Premium Trial:

Request an Annual Quote

Prescient Medicine, Erasmus MC Partner to Study Opioid Addiction Risk Test

NEW YORK — Prescient Medicine said this week that it has partnered with Dutch medical research institute Erasmus MC to evaluate its opioid addiction risk technology in a clinical study in the Netherlands.

Prescient offers a tes, called LifeKit Predict that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway. The assay uses multiplexed PCR and nucleic acid hybridization to analyze DNA extracted from buccal swabs.

The test, developed in collaboration with recently acquired AutoGenomics, was granted a breakthrough device designation by the US Food and Drug Administration in 2018.

According to Carlsbad, California-based Prescient, the study with Erasmus MC aims to confirm positive results from research completed in the US.

"A test like this is valuable to anyone prescribing opioids, not just in the United States," Prescient CEO Keri Donaldson said in a statement. "We are excited to expand the use of this test to the Netherlands and potentially help play a part in helping combat the opioid crisis that may be developing in the Netherlands and throughout the world."

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.